Share：
Share this content in WeChat
X
[Chinese] [PDF] 5 1
• Clinical Articles •
Diagnostic value of magnetic resonance diffusion-weighted imaging for T-staging between T1 and T2 of bladder cancer: A Meta-analysis
FENG Xinyao  LIU Yong  LUO Weidan 

Cite this article as: FENG X Y, LIU Y, LUO W D. Diagnostic value of magnetic resonance diffusion-weighted imaging for T-staging between T1 and T2 of bladder cancer: A Meta-analysis[J]. Chin J Magn Reson Imaging, 2026, 17(3): 54-59. DOI:10.12015/issn.1674-8034.2026.03.008.


[Abstract] Objective This study employed a meta-analysis approach to systematically evaluate the diagnostic performance of diffusion-weighted imaging (DWI) in staging bladder cancer, specifically in differentiating T1 or lower stages from T2 or higher stages.Materials and Methods A comprehensive literature search was conducted in CNKI, PubMed, and Embase databases (from the establishment to March 2025) using inclusion criteria. The quality assessment of diagnostic accuracy studies-2 (OUADAS-2) was used to assess the quality of the included studies. Heterogeneity testing was performed using RevMan 5.3 and Stata 18.0 statistical software. Meta-analysis of diagnostic sensitivity and specificity was conducted, with subsequent construction of summary receiver operating characteristic (SROC) curves and calculation of evaluation metrics including area under the curve (AUC).Results Twelve studies were included in the analysis. The pooled sensitivity of DWI for T-staging of bladder cancer was 0.89 [95% (confidence interval, CI): 0.78 to 0.95], specificity was 0.85 (95% CI: 0.77 to 0.90), AUC reached 0.92 (95% CI: 0.89 to 0.94), positive likelihood ratio (PLR) was 5.9 (95% CI: 3.9 to 8.8), negative likelihood ratio (NLR) was 0.13 (95% CI: 0.06 to 0.27), and diagnostic odds ratios (DOR) was 45 (95% CI: 19 to 109). Deek's funnel plot was basically symmetrical, and the slope coefficient was not statistically significant (P = 0.44), suggesting that there was no significant publication bias in the studies included inour analysis.Conclusions DWI demonstrates high diagnostic value in T-staging of bladder cancer and provides crucial reference information for clinical treatment decision-making.
[Keywords] urinary bladder neoplasms；neoplasm staging；magnetic resonance imaging；diffusion-weighted imaging；Meta-analysis

FENG Xinyao1, 2   LIU Yong2   LUO Weidan3*  

1 Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

2 Department of Magnetic Resonance, The Affiliated Hospital of Traditional Chinese Medicine, Southwest Medical University, Luzhou 646000, China

3 Department of Vascular Surgery, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

Corresponding author: LUO W, E-mail: luoweidan111@163.com

Conflicts of interest   None.

Received  2025-10-26
Accepted  2026-01-26
DOI: 10.12015/issn.1674-8034.2026.03.008
Cite this article as: FENG X Y, LIU Y, LUO W D. Diagnostic value of magnetic resonance diffusion-weighted imaging for T-staging between T1 and T2 of bladder cancer: A Meta-analysis[J]. Chin J Magn Reson Imaging, 2026, 17(3): 54-59. DOI:10.12015/issn.1674-8034.2026.03.008.

[1]
JUBBER I, ONG S, BUKAVINA L, et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors[J]. Eur Urol, 2023, 84(2): 176-190. DOI: 10.1016/j.eururo.2023.03.029.
[2]
CHAI Z Z, WANG X C. Research progress in predicting postoperative recurrence of bladder cancer using magnetic resonance imaging[J]. Chin J Magn Reson Imaging, 2025, 16(10): 202-207. DOI: 10.12015/issn.1674-8034.2025.10.032.
[3]
LEUNG D K, WONG C H, KO I C, et al. Global trends in the incidence, mortality, and risk-attributable deaths for prostate, bladder, and kidney cancers: a systematic analysis from the global burden of disease study 2021[J]. Eur Urol Oncol, 2025, 8(6): 1533-1543. DOI: 10.1016/j.euo.2025.05.007.
[4]
YAMADA Y, KOBAYASHI S, ISOSHIMA S, et al. The usefulness of diffusion-weighted magnetic resonance imaging in bladder cancer staging and functional analysis[J]. J Cancer Res Ther, 2014, 10(4): 878-882. DOI: 10.4103/0973-1482.138225.
[5]
LOPEZ-BELTRAN A, COOKSON M S, GUERCIO B J, et al. Advances in diagnosis and treatment of bladder cancer[J/OL]. BMJ, 2024, 384: e076743 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/38346808/. DOI: 10.1136/bmj-2023-076743.
[6]
JIANG S Y, ZHANG J. Application progress of multimodal imaging in diagnosis of muscular infiltration of bladder cancer[J]. J Clin Radiol, 2024, 43(2): 318-321. DOI: 10.13437/j.cnki.jcr.2024.02.027.
[7]
LÜ W C, LEI X H, WANG H Y, et al. A modified model of PANoptosisto identify prognosis and immunotherapy response in bladder cancer[J/OL]. Int J Biochem Cell Biol, 2024, 176: 106672 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/39368544/. DOI: 10.1016/j.biocel.2024.106672.
[8]
YIN H Y, ZHANG J, TIAN W Z, et al. The application value of quantitative parameters combined with vesical imaging-report and data system in distinguishing muscle-invasive bladder cancer[J]. J Clin Radiol, 2022, 41(5): 902-907. DOI: 10.13437/j.cnki.jcr.2022.05.016.
[9]
TANG D C, ZHOU S K, ZHANG G Y, et al. Analysis of risk factors of recurrence in non-muscle invasive bladder cancer patients after initial transurethral resection of bladder tumor[J]. China Oncol, 2023, 33(5): 478-483. DOI: 10.19401/j.cnki.1007-3639.2023.05.008.
[10]
JIN Y H, ZENG X T, LIU T Z, et al. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition)[J/OL]. Mil Med Res, 2022, 9(1): 44 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/35978389/. DOI: 10.1186/s40779-022-00406-y.
[11]
LIU H Q, ZHANG J J, ZHANG Z Q, et al. The value of intravoxel incoherent motion diffusion weighted imaging in the evaluation of bladder cancer grade and myometrial invasion[J]. Chin J Magn Reson Imaging, 2025, 16(9): 118-123. DOI: 10.12015/issn.1674-8034.2025.09.018.
[12]
WATANABE H, KANEMATSU M, KONDO H, et al. Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value [J]. AJR Am J Roentgenol, 2009, 192(5): 1361-1366. DOI: 10.2214/AJR.08.1430.
[13]
BADAWY M, FARG H, GADELHAK B, et al. Diagnostic performance of 3-tesla multiparametric MRI for assessment of the bladder cancer T stage and histologic grade[J/OL]. Egypt J Radiol Nucl Med, 2020, 51(1): 225 [2025-10-25]. https://link.springer.com/article/10.1186/s43055-020-00343-7. DOI: 10.1186/s43055-020-00343-7.
[14]
LIU S H, XU F J, XU T Y, et al. Evaluation of Vesical Imaging-Reporting and Data System (VI-RADS) scoring system in predicting muscle invasion of bladder cancer[J]. Transl Androl Urol, 2020, 9(2): 445-451. DOI: 10.21037/tau.2020.02.16.
[15]
ELSALAM S M ABD, ABDELBARY A M. Accuracy of diffusion-weighted magnetic resonance imaging in evaluation of muscle invasion and histologic grading of the urinary bladder carcinoma[J/OL]. Egypt J Radiol Nucl Med, 2020, 51(1): 48 [2025-10-25]. https://link.springer.com/article/10.1186/s43055-020-00163-9. DOI: 10.1186/s43055-020-00163-9.
[16]
ABD-KADHIM M, HUSSEIN M A, FAWZI H A. Role of diffusion-weighted MRI and dynamic contrast-enhanced MRI in early staging of bladder cancer[J/OL]. Ind Jour Publ Health Rese & Develop, 2019, 10(3): 431 [2025-10-25]. https://indianjournals.com/article/ijphrd-10-3-089. DOI: 10.5958/0976-5506.2019.00533.3.
[17]
DE HAAS R J, STEYVERS M J, FÜTTERER J J. Multiparametric MRI of the bladder: ready for clinical routine [J]. AJR Am J Roentgenol, 2014, 202(6): 1187-1195. DOI: 10.2214/AJR.13.12294.
[18]
KOBAYASHI S, KOGA F, YOSHIDA S, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness[J]. Eur Radiol, 2011, 21(10): 2178-2186. DOI: 10.1007/s00330-011-2174-7.
[19]
VAN DER POL C B, CHUNG A, LIM C, et al. Update on multiparametric MRI of urinary bladder cancer[J]. J Magn Reson Imaging, 2018, 48(4): 882-896. DOI: 10.1002/jmri.26294.
[20]
GUO J T, WANG X C. Research progress in multimodal function magnetic resonance imaging in staging and grading of bladder cancer[J]. Chin J Magn Reson Imaging, 2024, 15(2): 229-234. DOI: 10.12015/issn.1674-8034.2024.02.038.
[21]
HE K W, MENG X Y, FENG C, et al. Evaluation of muscular invasiveness of VI-RADS 2 bladder cancer based on DWI imaging features and quantitative parameters[J]. Radiol Pract, 2024, 39(6): 761-766. DOI: 10.13609/j.cnki.1000-0313.2024.06.008.
[22]
TALLON J, MCHUGH D, DOBBY B, et al. 1817 Comparison of target volume changes in T2W and DWI with ADC and cumulative delivered dose in muscle invasive bladder cancer[J]. Radiother Oncol, 2025, 206: S4343-S4344. DOI: 10.1016/S0167-8140(25)00671-1.
[23]
TALLON J, MCHUGH D, SWINTON M, et al. Comparison of DWI to T2 bladder target volume analysis for treatment adaptation in muscle invasive bladder cancer[J/OL]. J Med Imag Radiat Sci, 2024, 55(1): S7 [2025-10-25]. https://www.jmirs.org/article/S1939-8654(24)00072-9/abstract. DOI: 10.1016/j.jmir.2024.03.018.
[24]
CHANG L Y, XU X H, WU G T, et al. Predicting preoperative pathologic grades of bladder cancer using intravoxel incoherent motion and amide proton transfer-weighted imaging[J/OL]. Acad Radiol, 2023: S1076-S6332(23)00533-0 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/39492328/. DOI: 10.1016/j.acra.2023.09.044.
[25]
WHITING P F, RUTJES A W, WESTWOOD M E, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies[J]. Ann Intern Med, 2011, 155(8): 529-536. DOI: 10.7326/0003-4819-155-8-201110180-00009.
[26]
ZAMORA J, ABRAIRA V, MURIEL A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data[J/OL]. BMC Med Res Methodol, 2006, 6: 31 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/16836745/. DOI: 10.1186/1471-2288-6-31.
[27]
SETTEIN M M, SOBH D M, ETEBA S M, et al. Comparison between conventional and diffusion-weighted magnetic resonance imaging in predicting grade and stage of urinary bladder cancer[J/OL]. Egypt J Radiol Nucl Med, 2021, 52(1): 16 [2025-10-25]. https://link.springer.com/article/10.1186/s43055-020-00365-1. DOI: 10.1186/s43055-020-00365-1.
[28]
LEE M, SHIN S J, OH Y T, et al. Non-contrast magnetic resonance imaging for bladder cancer: fused high b value diffusion-weighted imaging and T2-weighted imaging helps evaluate depth of invasion[J]. Eur Radiol, 2017, 27(9): 3752-3758. DOI: 10.1007/s00330-017-4759-2.
[29]
LI Q, CAO B H, TAN Q X, et al. Prediction of muscle invasion of bladder cancer: a comparison between DKI and conventional DWI[J/OL]. Eur J Radiol, 2021, 136: 109522 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/33434860/. DOI: 10.1016/j.ejrad.2021.109522.
[30]
LI C, GU Z R, NI P Q, et al. The value of contrast-enhanced ultrasound and magnetic resonance imaging in the diagnosis of bladder cancer[J]. J Cancer Res Ther, 2021, 17(5): 1179-1185. DOI: 10.4103/jcrt.jcrt_1056_21.
[31]
JURI H, HIGASHIYAMA A, YAMAMOTO K, et al. Comparison of reduced field-of-view DWI and full field-of view DWI for the differentiation between non-muscle invasive bladder cancer and muscle invasive bladder cancer using VI-RADS[J/OL]. PLoS One, 2022, 17(7): e0271470 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/35857788/. DOI: 10.1371/journal.pone.0271470.
[32]
LI H Y, LIU L, SHI Q L, et al. Bladder cancer: detection and image quality compared among IShim, RESOLVE, and ss-EPI diffusion-weighted MR imaging with high b value at 3.0 T MRI[J/OL]. Medicine, 2017, 96(50): e9292 [2025-10-25]. https://pubmed.ncbi.nlm.nih.gov/29390388/. DOI: 10.1097/MD.0000000000009292.
[33]
ZHANG X X, GUO J X, YUN Y, et al. Differentiation of muscular invasion in bladder cancer: additional value of synthetic magnetic resonance imaging[J]. Acad Radiol, 2024, 31(10): 4076-4084. DOI: 10.1016/j.acra.2024.03.011.
[34]
ZHANG X X, YUN Y, WANG S Y, et al. The value of multi-directional high b-value DWI in the assessment of muscular invasion in bladder urothelial carcinoma: in comparison with VI-RADS[J]. Acad Radiol, 2025, 32(2): 844-854. DOI: 10.1016/j.acra.2024.09.056.
[35]
TAKEUCHI M, SASAKI S, ITO M, et al. Urinary bladder cancer: diffusion-weighted MR imaging: accuracy for diagnosing T stage and estimating histologic grade[J]. Radiology, 2009, 251(1): 112-121. DOI: 10.1148/radiol.2511080873.
[36]
NOCERA L, BANDINI M, BASILE G, et al. A1292 Chemotherapy vs. immunotherapy as neoadjuvant therapies in cisplatin-eligible patients undergoing radical cystectomy for muscle invasive bladder cancer[J]. Eur Urol, 2023, 83: S1879-S1880. DOI: 10.1016/S0302-2838(23)01330-1.
[37]
SANTANGELO A, SCILIPOTI P, ZAURITO P, et al. P454–Impact of timing between neoadjuvant therapy and radical cystectomy on overall survival outcomes: Findings from a single high-volume center[J/OL]. Eur Urol, 2025, 87: S465 [2025-10-25]. https://www.sciencedirect.com/science/article/abs/pii/S0302283825034037via%3Dihub. DOI: 10.1016/j.eururo.2025.09.2894.

PREV The value of deep learning models based on multiparameter MRI in the preoperative prediction of tumor deposits in rectal cancer
NEXT The value of blood oxygen level dependent MRI in assessing treatment response and prognostic risk factors in cervical squamous cell carcinoma undergoing neoadjuvant chemotherapy
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn